TailorMed, a platform that allows healthcare providers to manage their finances, check health plans and estimate out-of-pocket costs for uninsured patients, announced a $40 million financing round, combining equity and debt, led by Windham Capital Partners.
Samsung Next, BrightEdge, Citi Impact Fund and the investment arms of OSF Healthcare, Ballad Ventures, Inception Health, UnityPoint Health Ventures, UH Ventures and Providence Ventures also participated in the round.
The company also received ongoing funding from early investors Almeda Ventures, Sanara Ventures, Triventures, Accelmed and Bridges.
“In the past six years, we’ve built incredible momentum by empowering our network of leading health systems, pharmacies, and life science companies to drive affordability on a massive scale,” Srulik Dvorsky, CEO and cofounder of TailorMed, said in a statement.
“But we’re just getting started. This new funding will fuel our mission to break down even more barriers to care, creating a healthcare system where affordability is the standard, not the exception, and working with patients and care teams to alleviate whatever barrier that comes next. We’re excited to have the backing of Windham Capital Partners and other forward-thinking investors who share our vision of transforming access to care for millions.”
Genomics-based precision oncology company OneCell Diagnostics raised $16 million in an oversubscribed Series A funding round, which the India-based company will use to expand into the U.S. market.
Celesta Capital led the round, with participation from Cedars Sinai, Singularity Ventures, Eragon and Tenacity Ventures.
Michael Marks, Celesta Capital’s founding managing partner, and Dr. James Rothman, Celesta senior advisor and Nobel Laureate, will join the company’s board of directors.
OneCell develops technology for precision oncology liquid biopsy diagnostics. The company’s offerings include tumor genomics that helps identify target drugs for advanced cancers and blood-based monitoring to analyze cancer progression and treatment responses.
It also offers AI-enabled digital pathology to improve treatment decisions and single-cell multi-omics to predict tumor behavior and potential recurrence.
“We see a future where everyone has access to high-quality, life-saving cancer testing and this funding is a powerful validation of our vision,” Mohan Uttarwar, CEO and cofounder at OneCell Diagnostics, said in a statement.
“By integrating our single-cell multi-omics analytics with next-generation liquid biopsy approaches, we have the opportunity to break new ground in delivering accurate, personalized cancer care worldwide.”
dannce.ai, which offers a phenotyping platform to digitize clinical assessments used by doctors to measure movement, raised $2.6 million in pre-seed funding led by LDV Capital following initial investment from Glasswing Ventures.
The Leo Lion Company, Merck Digital Sciences Studio and Duke Capital Partners participated in the round.
The company offers an AI-enabled phenotyping platform that allows clinicians and drug developers to perform motion analysis on patients with neurological conditions. The video-based platform aims to help characterize treatment responses and improve neurological care.
“One in ten individuals will be diagnosed with a movement disorder during their lifetime. We are creating a world where aging adults have broad access to objective neurological screenings and new therapies for these disorders are also objectively validated,” Rob Baldoni, CEO and cofounder of dannce.ai, said in a statement.
“We have brought together a powerhouse team with Tim and Jesse, two of the world’s leading experts in behavioral quantification, Shereen Shermak, our COO, and Joe Chan, our CTO, who have an extensive track record of scaling ventures and building products. We will be the first to provide clinicians and drug developers with a solution that characterizes drug effects and optimizes neurological care.”
